GlassScriptPhysician profile
Deborah A Goss
NPI 1790765949
$8,424.50
in general payments reported to CMS, 2019-2025
26 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,160 · 2020: $1,098 · 2021: $337 · 2022: $821 · 2023: $417 · 2024: $931 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706 · Education: $152 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.98 |
| Education | $152.36 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $5,025.66 | 2019-2025 | Inspire |
| Glaxosmithkline, LLC. | $477.01 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $442.39 | 2023-2025 | Airsupra, Breztri, Symbicort |
| Harmony Biosciences LLC | $328.32 | 2022-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $314.86 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $252.50 | 2024-2025 | |
| Olympus Corporation of The Americas | $232.64 | 2022 | |
| Intuitive Surgical, INC. | $185.28 | 2019 | |
| Axsome Therapeutics, INC. | $173.82 | 2024-2025 | Sunosi |
| Baxter Healthcare | $165.05 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Pulmonx Corporation | $137.35 | 2019-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Zoll Respicardia, INC. | $129.57 | 2021 | |
| Eisai INC. | $125.00 | 2019 | |
| Ethicon INC. | $123.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.21 | 2019-2025 | Jascayd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $49.97 | 2024-2025 | Arikayce |
| Verona Pharma, INC. | $34.45 | 2025 | Ohtuvayre |
| Electromed, INC. | $31.05 | 2025 | Smartvest |
| 3b Medical, INC. | $22.73 | 2025 | Luna |
| Lilly USA, LLC | $19.35 | 2025 | Zepbound |
| United Therapeutics Corporation | $18.11 | 2021 | |
| Celgene Corporation | $17.35 | 2021 | |
| Amgen INC. | $16.53 | 2024 | Tezspire |
| Xeris Pharmaceuticals, INC. | $13.32 | 2024 | Keveyis |
| Idorsia Pharmaceuticals US INC | $11.73 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Goss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.